Verve Therapeutics, Inc closed the private placement of 2,296,317 shares at an issue price of price of $10 per share on December 1, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.19 USD | +0.97% | -1.70% | -62.77% |
May. 31 | Verve Therapeutics Names Troy Lister Chief Scientific Officer | MT |
May. 31 | Verve Therapeutics, Inc. Announces Executive Changes | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
820.3 USD | +0.65% | +1.60% | 739B | ||
5.19 USD | +0.97% | -1.70% | 436M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-62.77% | 436M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- VERV Stock
- News Verve Therapeutics, Inc.
- Verve Therapeutics, Inc. announced that it has received $22.96317 million in funding from Eli Lilly and Company